Takashi Nakamura

Takashi Nakamura

Auto-generated profile, based on publicly available information

Takashi Nakamura

Department of Biochemistry, Tokyo Dental College

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
TFToshifumi Fujiwara
Toshifumi Fujiwara
SYShiqiao Ye
Shiqiao Ye
TCThiago Castro-Gomes
Thiago Castro-Gomes
CWCaylin G. Winchell
Caylin G. Winchell
NANorma W. Andrews
Norma W. Andrews
HZHaibo Zhao
Haibo Zhao
Mutations of the Plekhm1 gene in humans and rats cause osteopetrosis, an inherited bone disease characterized by diminished bone resorption by osteoclasts. PLEKHM1 binds to RAB7 and is critical for lysosome trafficking. However, the molecular mechanisms by which PLEKHM1 regulates lysosomal pathways remain unknown. Here, we generated germline and conditional Plekhm1 -deficient mice. These mice displayed no overt abnormalities in major organs, except for an increase in trabecular bone mass. Furthermore, loss of PLEKHM1 abrogated the peripheral distribution of lysosomes and bone resorption in osteoclasts. Mechanistically, we indicated that DEF8 interacts with PLEKHM1 and promotes its binding to RAB7, whereas the binding of FAM98A and NDEL1 with PLEKHM1 connects lysosomes to microtubules. Importantly, suppression of these proteins results in lysosome positioning and bone resorption defects similar to those of Plekhm1 -null osteoclasts. Thus, PLHKEM1, DEF8, FAM98A, and NDEL1 constitute a molecular complex that regulates lysosome positioning and secretion through RAB7.

21 August 2024 in Nature
Verified
Journal Article
Closed access
PDF file
KNKazutaka Nakamura
Kazutaka Nakamura
MTMasayuki Tsukasaki
Masayuki Tsukasaki
TTTakaaki Tsunematsu
Takaaki Tsunematsu
MYMinglu Yan
Minglu Yan
YAYutaro Ando
Yutaro Ando
HTHiroshi Takayanagi
Hiroshi Takayanagi

1 August 2006 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
KYKo Yasura
Ko Yasura
YNYasuaki Nakagawa
Yasuaki Nakagawa
MKMasahiko Kobayashi
Masahiko Kobayashi
HKHiroshi Kuroki
Hiroshi Kuroki
TNTakashi Nakamura
Takashi Nakamura
Background: There are growing concerns about thermal chondroplasty using radiofrequency energy to treat partial-thickness cartilage defects. However, most studies emphasize effects on chondrocyte viability, and other factors such as mechanical properties are less studied. Hypothesis: Radiofrequency energy may cause significant effects on articular cartilage other than chondrocyte viability. Study Design: Controlled laboratory study. Methods: Human osteoarthritic cartilage samples were obtained from total knee arthroplasty, and monopolar radiofrequency energy was applied using commercially available equipment. Material properties (compressive stiffness, surface roughness, and thickness) just before and after thermal treatment were determined using ultrasound. A series of biochemical analyses were also performed after explant culture of the samples. Results: The cartilage surface became smoother by radiofrequency energy, whereas cartilage stiffness or thickness was not altered significantly. Collagen fibrils, especially in the superficial layers, were converted to denatured form, whereas proteoglycan contents released in the media as well as retained in the tissue remained unchanged. The concentrations of matrix metalloproteinases (MMP-1 and MMP-2) were reduced remarkably. Conclusion: Radiofrequency energy is able to create a smooth cartilage surface and reduce catabolic enzymes at the cost of collagen denaturation and chondrocyte death in the superficial layers. The stiffness of the cartilage is not changed at time zero. Clinical Relevance: Further animal as well as clinical studies will be necessary to fully evaluate the long-term effects of radiofrequency energy.

24 October 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HOHiroyuki Ogura
Hiroyuki Ogura
TNTakashi Nakamura
Takashi Nakamura
TITakenobu Ishii
Takenobu Ishii
ASAkiko Saito
Akiko Saito
SOShoko Onodera
Shoko Onodera
TAToshifumi Azuma
Toshifumi Azuma

1 December 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
RSRemya Sreedhar
Remya Sreedhar
SASomasundaram Arumugam
Somasundaram Arumugam
VKVengadeshprabhu Karuppagounder
Vengadeshprabhu Karuppagounder
Rajarajan Amirthalingam ThandavarayanRajarajan Amirthalingam Thandavarayan
Rajarajan Amirthalingam Thandavarayan
VGVijayasree Giridharan
Vijayasree Giridharan
KWKenichi Watanabe
Kenichi Watanabe

13 May 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
HNHaruo Nishijima
Haruo Nishijima
TKTamaki Kimura
Tamaki Kimura
FMFumiaki Mori
Fumiaki Mori
KWKoichi Wakabayashi
Koichi Wakabayashi
IKIku Kinoshita
Iku Kinoshita
MTMasahiko Tomiyama
Masahiko Tomiyama
Background: It remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies using animal models have failed to show young-onset Parkinson’s disease enhances LID.Objectives: To evaluate the association of age at dopaminergic denervation (onset age) and initiation of L-dopa treatment (treatment age) with LID development in model rats.Methods: We established rat models of young- and old-lesioned Parkinson’s disease (6-hydroxydopamine lesions at 10 and 88 weeks of age, respectively). Dopaminergic denervation was confirmed by the rotational behavior test using apomorphine. Rats in the young-lesioned group were allocated to either L-dopa treatment at a young or old age, or saline treatment. Rats in the old-lesioned group were allocated to either L-dopa treatment or saline group. We evaluated L-dopa-induced abnormal involuntary movements during the 14-day treatment period. We also examined preprodynorphin mRNA expression in the striatum (a neurochemical hallmark of LID) and the volume of the medial globus pallidus (a pathological hallmark of LID).Results: LID-like behavior was enhanced in L-dopa-treated young-lesioned rats compared with L-dopa-treated old-lesioned rats. Preprodynorphin mRNA expression was higher in L-dopa-treated young-lesioned rats than in in L-dopa-treated old-lesioned rats. The volume of the medial globus pallidus was greater in L-dopa-treated young-lesioned rats than in L-dopa-treated old-lesioned rats. Treatment age did not affect LID-like behavior or the degree of medial globus pallidus hypertrophy in the young-lesioned model.Conclusion: Both dopaminergic denervation and L-dopa initiation at a young age contributed to the development of LID; however, the former may be a more important factor.